April 2, 2026

NGS Platform Comparison 2026 for Clinical mNGS

Choosing the right sequencing platform for clinical and research mNGS requires balancing throughput, turnaround time, read quality, and per-sample cost — tradeoffs that have shifted dramatically as new platforms enter the market. In a micro-webinar, Dr. Mengchu Wu presented an NGS platform comparison covering both established players and the wave of new instruments commercially launched in 2023-2024, analyzing which sequencing platforms fit metagenomic applications in research and clinical settings.

Key Takeaways

Four new short-read NGS platforms (Singular Genomics, Element Biosciences, Ultima Genomics, MGI/Complete Genomics) launched commercially in 2023-2024, breaking Illumina’s near-monopoly
For mNGS, turnaround time and cost-per-sample matter more than maximum throughput, since most metagenomic samples need only 5 million reads
Complete Genomics offers the fastest sequencing speed for 100 base pair reads among current mid-output platforms
Element Biosciences addresses sequencing accuracy through novel chemistry that reduces phasing and pre-phasing errors
Nanopore (third-generation sequencing) is fundamentally different from all short-read platforms and will be covered in a separate assessment

Quick Answer: Which Sequencing Platform Fits mNGS?

For mNGS labs comparing sequencing platforms in 2026, Illumina remains the safest short-read choice when validated workflows and library compatibility matter most. MGI or Complete Genomics is attractive when faster short-read turnaround and per-run economics are priorities. Element Biosciences is strongest when base quality is the deciding factor, while Singular Genomics offers flexible benchtop flow-cell loading for mixed research workloads. Ultima Genomics fits very large whole-genome or high-batch projects more than routine mNGS. Oxford Nanopore is the clearest long-read option when real-time sequencing, taxonomic resolution, or antimicrobial-resistance gene context matters more than short-read accuracy.

For infectious-disease mNGS, the platform decision should not start with cost per gigabase alone. The practical comparison is whether the platform can support low-input or host-depleted samples, deliver enough usable microbial reads at roughly 5 million reads per sample, and return results fast enough for the intended clinical or research workflow.

NGS Platform Comparison for Clinical Research and mNGS

For `ngs platforms` and `next generation sequencing platform comparison` searches, the useful comparison is not only instrument output. Clinical research teams also need to know whether the platform supports low-input samples, microbiology workflows, outsourced sequencing decisions, and validated downstream analysis.

Illumina: best fit for validated short-read workflows, broad library compatibility, and routine clinical research use. Watch for wasted capacity when high-output instruments are used for small mNGS batches.
MGI / Complete Genomics: best fit for fast short-read turnaround and cost-sensitive mid-output runs. Confirm local support and library compatibility before switching.
Element Biosciences: best fit when base quality is the priority. Longer run times may not fit urgent mNGS turnaround.
Singular Genomics: best fit for flexible benchtop runs with mixed applications or split flow cells. Ecosystem maturity and validation depth matter.
Ultima Genomics: best fit for very large batches and whole-genome-scale projects. The scale may exceed routine microbiology mNGS needs.
Oxford Nanopore: best fit for long reads, real-time sequencing, taxonomic resolution, and AMR context. Accuracy, library prep, and analysis workflows differ from short-read platforms.

When comparing outsourced next-generation sequencing providers, ask which platform they use, whether they support host-depleted or low-input mNGS samples, what read depth they target per sample, and whether their analysis workflow is validated for pathogen detection rather than generic genome sequencing.

The NGS Landscape From 454 to the Present

Next-generation sequencing (NGS) has been commercially available since approximately 2005, when Roche launched the 454 platform — the first sequencing-by-synthesis instrument to reach the market. Illumina followed in 2007 with the Genome Analyzer, and Life Technologies (now Thermo Fisher Scientific) entered with the SOLiD platform before pivoting to Ion Torrent semiconductor sequencing.

By 2016, the 454 platform was discontinued due to market competition, leaving two dominant players: Illumina (fluorescent-tag sequencing by synthesis) and Thermo Fisher (hydrogen-detection sequencing by synthesis via Ion Torrent). These companies pursued different strategies. Illumina focused on scaling output, culminating in the NovaSeq X platform with 3-8 terabytes per run. Thermo Fisher emphasized automation, developing sample-to-result workflows and achieving in vitro diagnostic (IVD) approval for oncology panels.

The competitive landscape shifted in 2023-2024 as key sequencing patents expired or were settled through litigation, opening the door for new entrants.

New Short-Read Platforms Entering the Market

Platform comparison snapshot for mNGS labs.

For laboratories comparing NGS platforms in 2025-2026, the best choice depends on whether the run is designed for whole-genome sequencing, core-facility batch work, or metagenomic pathogen detection. Whole-genome runs reward maximum gigabase output and low cost per gigabase. mNGS workflows usually reward shorter turnaround, lower minimum output, flexible flow cell loading, and reliable performance at roughly 5 million reads per sample.

Illumina NextSeq / NovaSeq: Best fit for broad clinical and research use with established workflows. The ecosystem and validated library chemistry are strong, but high-output instruments can waste capacity for small mNGS batches.
MGI / Complete Genomics: Best fit for fast short-read turnaround and cost-sensitive mid-output runs. It is attractive when speed and per-run economics matter, subject to library compatibility and local support.
Element Biosciences: Best fit for accuracy-focused short-read sequencing. It is useful when base quality is prioritized, but longer run times may not fit urgent mNGS workflows.
Singular Genomics: Best fit for flexible benchtop flow cell configuration. It is useful for mixed workloads where mNGS shares instrument time with WGS, RNA-seq, or panels.
Ultima Genomics: Best fit for very high-throughput whole-genome and large-batch work. Cost per gigabase can be strong, but the scale may exceed routine mNGS sample volume.
Oxford Nanopore: Best fit for long-read, real-time sequencing. It is valuable for taxonomic resolution and AMR context, with different accuracy and workflow tradeoffs from short-read platforms.

Singular Genomics: Singular Genomics offers a benchtop sequencer that accepts up to four flow cells simultaneously, providing flexibility for laboratories running mixed applications. Each flow cell is available in low-output and high-output configurations. A lab can run whole genome sequencing on one flow cell, RNA sequencing on another, and metagenomic sequencing on a third within the same instrument run.
Element Biosciences: Element Biosciences targets sequencing accuracy with proprietary chemistry designed to address phasing and pre-phasing errors. In standard sequencing-by-synthesis, millions of DNA clusters synthesize in parallel, but synthesis can become desynchronized — some clusters add one nucleotide while others add two. This “phasing” introduces errors that accumulate over the read length and degrade quality scores. Element’s chemistry reduces this effect, producing higher-accuracy reads. The tradeoff is sequencing speed: Element’s runs take longer, with some configurations exceeding 20 hours for 150 base pair reads.
Ultima Genomics: Ultima Genomics occupies the high-throughput tier, comparable to Illumina’s NovaSeq X series. Their floor-standing instrument replaces flow cells with silicon wafers and can queue up to six wafers for automated sequential processing. The per-million-read cost is lower than NovaSeq, and their proprietary ppmSeq technology improves detection of single nucleotide variants (SNVs) at very low allele frequencies — particularly relevant for cell-free DNA (cfDNA) oncology applications. However, the output scale exceeds what most metagenomic laboratories require for routine work.
MGI / Complete Genomics: MGI, operating under the Complete Genomics brand in the US market, uses a nanoball-based amplification and sequencing approach that differs from Illumina’s bridge amplification. Their mid-output instruments support up to two flow cells, and the platform’s distinguishing feature is sequencing speed. For 100 base pair reads, Complete Genomics delivers the fastest turnaround time among the mid-output platforms compared in the webinar.

Third-Generation Sequencing: Oxford Nanopore

ONT sequencing represents a fundamentally different approach. Rather than sequencing by synthesis, nanopore technology detects electrical signals as native DNA strands pass through protein pores. This enables long reads (tens of kilobases), direct detection of base modifications, and real-time data streaming without synthesis chemistry.

For mNGS, long reads improve taxonomic classification accuracy and enable antimicrobial resistance gene context that short fragments cannot resolve. ONT platforms range from the portable MinION to higher-throughput instruments, with the Flongle flow cell offering the lowest per-run cost at approximately $90.

What Matters for mNGS Platform Selection

The webinar identified five evaluation criteria for metagenomic applications: quality, total output, instrument flexibility, turnaround time, and cost (both capital expenditure and operational expense). For clinical mNGS, the priority ranking differs from research applications.

Quality operates at two levels. Base-level quality (Q-scores) measures the probability of an incorrect base call. Mapping quality depends on read length — longer reads align more accurately to reference genomes, improving pathogen identification confidence. For mNGS, mapping quality often matters more than raw base quality.

Output flexibility is critical because most metagenomic samples require only about 5 million reads per sample. High-throughput platforms waste capacity unless laboratories can batch enough samples to fill a run. Platforms with multiple flow cell options or lower minimum output thresholds better match mNGS workflows.

Turnaround time is especially important for clinical pathogen identification, where results within 24 hours can influence treatment decisions. Among the mid-output platforms, Complete Genomics offers the fastest sequencing time for short reads, while Element Biosciences’ accuracy-focused chemistry results in slower runs that may not complete within a 24-hour window.

Whole-Genome Runs vs mNGS Platform Selection

A platform that ranks well for whole-genome sequencing is not automatically the best platform for metagenomic sequencing. Whole-genome runs usually optimize for maximum output, lowest cost per gigabase, automation, and large sample batches. A core facility choosing a sequencer for WGS may prefer the instrument that produces the most data per run at the lowest unit cost.

mNGS has a different decision frame. Most infectious-disease workflows need enough reads to identify low-abundance organisms after host depletion, but they do not always need a full high-throughput flow cell. For mNGS, the practical questions are:

Can the platform support low-input or host-depleted samples without forcing excessive batching?
Can the library preparation chemistry work with microbial and host-depleted DNA inputs?
Can the run finish quickly enough for a clinically useful turnaround time?
Does the cost per 5 million usable reads beat the apparent cost per gigabase?
Is the downstream analysis workflow validated for the read length and error profile?

That is why this comparison treats cost per gigabase as only one metric. It matters for whole-genome and large core-facility runs, but mNGS platform selection also depends on sample input, microbial read yield, turnaround time, and workflow compatibility.

Turnaround Time and Cost Compared Across Platforms

The webinar presented side-by-side specifications for mid-output platforms (Complete Genomics, Element Biosciences, Illumina NextSeq series, and Singular Genomics), comparing output per flow cell, number of samples per flow cell at 5 million reads, sequencing time for 100 base pair reads, instrument cost, and per-run reagent cost.

With new platforms entering the market, both instrument prices and sequencing reagent costs are trending downward. For laboratories evaluating platforms specifically for mNGS, the key calculation is cost per 5 million usable reads (the minimum depth for pathogen identification using PaRTI-Seq analysis) rather than cost per gigabase alone.

Cost per gigabase is useful when ranking platforms for whole-genome sequencing, high-throughput DNA sequencing, or large core-facility runs. For metagenomics, a platform can look inexpensive per gigabase but still be inefficient if the run size is too large, the minimum batch size is too high, or the library chemistry is not well matched to low-input host-depleted samples. The mNGS cost calculation should include sequencing reagents, unused capacity, library preparation, host depletion, analysis, and repeat-run risk.

How Micronbrane Medical’s Workflow Adapts to Multiple Platforms

Micronbrane Medical’s mNGS workflow — host depletion with the Devin Filter, DNA extraction with mNGS-grade reagents, and library construction with the Unison Ultra Low Library Kit — is currently compatible with Illumina platforms. The company is actively developing compatibility with additional platforms identified as particularly promising for metagenomic applications.

The upstream sample processing (host depletion and DNA extraction) is platform-agnostic. The platform-specific component is library preparation, where adapter chemistry must match the sequencing instrument. As sequencing costs decrease across all platforms, the relative cost impact of upstream sample processing — particularly host depletion — becomes an even more significant lever for reducing total per-sample cost.

About the Speaker

Dr. Mengchu Wu is the co-founder, CEO, and Chairwoman of Micronbrane Medical. She previously held executive positions at HGT and Vela Diagnostics and earned her PhD in biomedical sciences at the University of Massachusetts Chan Medical School.